Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shumisheng plant extract is a botanical drug product derived from the fruit of *Ziziphus jujuba* (Chinese jujube), specifically standardized for its content of cyclic adenosine monophosphate (cAMP). It is primarily utilized in China as an adjuvant therapy for hematological conditions, including chemotherapy-related anemia (CRA), leukopenia, and thrombocytopenia. As a second messenger, cAMP plays a crucial role in various cellular processes; in the context of anemia, it is thought to promote the proliferation and differentiation of hematopoietic stem cells and potentially synergize with erythropoietin (EPO) to stimulate red blood cell production. Clinical studies, such as those conducted at Changzhi People's Hospital, evaluate its efficacy when combined with recombinant human erythropoietin (rhEPO) for managing anemia in patients with non-myeloid malignancies undergoing chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shumisheng plant extract.